GSK plc (GSK) president reports acquisition of notional ADS in savings plan

Rhea-AI Filing Summary

GSK plc reported that Maya Martinez-Davis, President, acquired notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account. The transaction involved 9.016 ADS at a price of $52.9600 per ADS on 7 August 2026 on the New York Stock Exchange.

Key Figures

ADS volume acquired: 9.016 ADS ADS price: $52.9600 per ADS Transaction date: 2026-08-07

3 metrics

ADS volume acquired 9.016 ADS Notional ADS acquired within GSK Executive Supplemental Savings Plan account

ADS price $52.9600 per ADS Price of American Depositary Shares in the reported transaction

Transaction date 2026-08-07 Date of acquisition of notional ADS by the GSK president

Key Terms

American Depositary Shares, Executive Supplemental Savings Plan, notional ADS, Legal Entity Identifier

4 terms

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS')"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Executive Supplemental Savings Plan financial

"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan"

notional ADS financial

"Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account"

Legal Entity Identifier regulatory

"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"

A legal entity identifier (LEI) is a unique, standardized code that functions like a global ID card for businesses and organizations involved in financial markets. It helps investors and regulators reliably identify who is on the other side of a deal, trace ownership and links between firms, and reduce confusion or fraud — improving transparency for reporting, risk assessment, and cross-border trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/11/2026 - 11:03 AM Accepted by SEC EDGAR 08/11/2026 - 11:03 AM Learn about SEC filing dates

FAQ

What insider transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that Maya Martinez-Davis, President, acquired 9.016 notional ADS in her GSK Executive Supplemental Savings Plan account at $52.9600 per ADS on 7 August 2026 on the New York Stock Exchange.

Who is the GSK (GSK) executive involved in the August 2026 ADS transaction?

The executive involved is Maya Martinez-Davis, identified as President. She acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account as reported for the transaction dated 7 August 2026.

What financial instrument was involved in the GSK (GSK) transaction?

The transaction involved American Depositary Shares (ADS) of GSK, identified by ISIN US37733W2044. These ADS represent GSK equity and were acquired notionally within an executive supplemental savings plan.

At what price were the GSK (GSK) ADS acquired by the executive?

The notional ADS were acquired at a price of $52.9600 per ADS. The reported transaction covers 9.016 ADS credited to the executive’s GSK Executive Supplemental Savings Plan account.

On what date and market did the GSK (GSK) ADS transaction occur?

The transaction took place on 7 August 2026 on the New York Stock Exchange (XNYS). It reflects acquisition of notional American Depositary Shares within an executive supplemental savings plan.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		$52.9600	9.016
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-08-07
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 11, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc